In the era of Breakthrough Therapy and Fast Track drug designations, chemistry, manufacturing and controls (CMC) submissions can cause delays to bring a drug to market, said Drew Barlow, vice president, regulatory affairs at Syner-G Pharma Consulting. Companies need to provide enough information to satisfy the regulatory requirements while recognizing that providing too much information early will […]
Close close